WebRoflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). ... Diarrhea, weight loss, stomach/abdominal pain, nausea, loss of appetite, headache, or dizziness may occur. If any of these effects persist or worsen ... WebMonitor weight regularly. If unexplained or clinically significant weight loss occurs, evaluate weight loss and consider discontinuation of roflumilast. Assess mental status (orientation, mood, behavior) before and periodically during therapy. Assess for suicidal tendencies.
Side-effects of roflumilast - The Lancet
Web10 Feb 2024 · Roflumilast and its active N-oxide metabolite selectively inhibit phosphodiesterase-4 (PDE4) leading to an accumulation of cyclic AMP (cAMP) within inflammatory and structural cells important in the pathogenesis of COPD. ... Weight loss: Weight loss has occurred; monitor weight regularly. If unexplained or significant weight … Web1 Sep 2012 · In the present study, patients in the roflumilast group had a mean weight change of −1.9 kg. However, patients in the placebo group also lost weight, with a mean change of −1.2 kg; the difference between treatment groups … black leather sofa ebay uk
Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on …
Web1 Dec 2013 · Weight loss and an increased risk of psychiatric events have also been reported in association with roflumilast use. As roflumilast is rapidly converted to its active metabolite via cytochrome P-450 (CYP) isoenzymes, coadministration with strong CYP inducers is not recommended. Web28 Sep 2024 · Weight loss of at least 5% was associated with improved asthma control, indicating that interventions other than roflumilast promoting weight loss may have efficacy for the treatment of poorly controlled asthma in people with obesity. Clinical trial registered with www.clinicaltrials.gov (NCT 03532490). WebThe most frequent AEs are diarrhea, reduced appetite, weight loss, abdominal pain, sleep disturbance and headache. A recent meta-analysis showed that roflumilast significantly increased AEs such as diarrhea (RR 2.945, P<0.001) and weight loss (RR 3.814, P<0.001) . Randomized controlled clinical trials (RCTs) do not always reflect a real-world ... black leather sofa feng shui earth